Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 10/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193596 | 0.92 | LMNA (0.87) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL285379 | 0.92 | LMNA (0.87) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL9410640 | 0.91 | LMNA (0.79) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL285147 | 0.91 | LMNA (0.79) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL8966859 | 0.90 | LMNA (0.94) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL6420868 | 0.90 | LMNA (0.94) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL8425098 | 0.90 | LMNA (0.94) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL13394000 | 0.90 | LMNA (0.94) | LMNATSHRMAPTPMP22HBB | |
| SCHEMBL26123316 | 0.90 | LMNA (0.80) | LMNATSHRMAPTPMP22HBB | |
| Capecitabine SCHEMBL12948190 | 0.89 | LMNA (1.00) | LMNATSHRMAPTPMP22HBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2019-08-29 | — | — | US | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | LMNA 3483/4885TSHR 4376/4885MAPT 4121/4885 |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | PHOSPHO1, EGLN3, HIF1AN | LMNA 1752/4885TSHR 2306/4885MAPT 2393/4885 |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | LMNA 3483/4885TSHR 4376/4885MAPT 4121/4885 |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | LMNA 3483/4885TSHR 4376/4885MAPT 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.